Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 5, 2016, Pages 468-475

  Cohen, Jeffrey A ^a   Khatri, Bhupendra ^b   Barkhof, Frederik ^c   Comi, Giancarlo ^d   Hartung, Hans Peter ^e   Montalban, Xavier ^f   Pelletier, Jean ^g   Stites, Tracy ^h   Ritter, Shannon ^h   Von Rosenstiel, Philipp ⁱ   Tomic, Davorka ^h   Kappos, Ludwig ^j  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WFHC   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g University of Aix Marseille   (France)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ BIOGEN   (United States)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON BETA-1A; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROIMAGING; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84968754649     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-310597     Document Type: Article

References (17)

1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
2. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-9.
3. [No authors listed]. 2014 Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014) MS Journal Online: Poster Session 1. Mult Scler 2014;20(1 Suppl):67-284.
4. Rio J, Castillo J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15:848-53.
5. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006;15:241-3.
6. Martinez-Yelamos S, Martinez-Yelamos A, Martin Ozaeta G, et al. Regression to the mean in multiple sclerosis. Mult Scler 2006;12:826-9.
7. Kappos L, Connor PO, Radue E-W, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology 2015;84:1582-91.
8. Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol 2014;71:269-70.
9. Khatri B, Barkhof F, Comi G, et al. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN-b1a: results from a phase 3, active-controlled study (TRANSFORMS) (PD5.006). Neurology 2012;78:PD5.006.
10. Rio J, Rovira A, Tintore M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008;14:479-84.
11. Prosperini L, Gallo V, Petsas N, et al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009;16:1202-9.
12. Prosperini L, Mancinelli CR, De Giglio L, et al. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler 2014;20:566-76.
13. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
14. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40.
15. Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207.
16. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-9.
17. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56. doi:10.1016/S1474-4422(14)70049-3